İrem AKOVA, Öznur HASDEMİR, Hayriye TÜRKOĞLU

BİR İLDE 40-69 YAŞ KADINLARDA MEME KANSERİ TARAMALARININ DEĞERLENDİRİLMESİ Evaluation of Screening For Breast Cancer in Women of Age 40-69 in a Province

BİR İLDE 40-69 YAŞ KADINLARDA MEME KANSERİ

Anahtar Kelimeler:

BİR İLDE 40-69 YAŞ KADINLARDA MEME KANSERİ TARAMALARININ DEĞERLENDİRİLMESİ Evaluation of Screening For Breast Cancer in Women of Age 40-69 in a Province

Effect of Prostaglandin E2 on Labor Induction in Postdate, Nulliparous Pregnancies

Objective: The aim of this study, is to evaluate the epidemiologic and clinical of pregnancy cases who arenulliparous and postdate with labor induction of prostaglandin E2 (dinoprostone) in the last 2 years in ourhospital.Materials and Methods: In my study, I examined 136 nullipar pregnants who were given induction withdinoprostone due to postdate (gestational week ≥ 41 weeks).Results: The rate of cesarean delivery who dinoprostone applied, in nulliparous and postdate pregnancieswas 31.6 %. The patients who delivered vaginally after dinoprostone induction were compared with thosewho delivered by cesarean section after dinoprostone induction. Fetal distress (48.8 %), failure for laborprogression (32.5 %) and cephalopelvic disproportion (18.6 %) were the most frequent indications forcesarean delivery. The rates of neonatal intensive care needs in the postpartum period were 3.2 % in thevaginal delivery group and 4.6 % in the cesarean delivery group, approximately were similar for both groups.Conclusion: Dinoprostone is safe and efficient agent used for cervical maturation and labor induction at

Keywords:

Labor induction, prostaglandin E, vaginal delivery cesarean section,

PDF

___

1. Ferlay J, Soerjomataram I, Dıkshıt R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer. 2015;136:359-386. doi:10.1002/ijc.29210 PMID:25220842 2. Keskinkılıç B, Gültekin M, Karaca AS, Öztürk C, Boztaş G, Karaca M, et al. Türkiye Kanser Kontrol Programı, T.C. Sağlık Bakanlığı Türkiye Halk Sağlığı Kurumu, Yayın No: 987, Ankara, Türkiye: Anıl Reklam Matbaa, 2016;18-49. 3. Parkin DM, Bray F, Ferlay J, Pisani P. Global Cancer Statistics, 2002. CA Cancer J Clin. 2005;55:74–108. 4. Bjurstam N, Björneld L, Warwick J, Sala E, Duffy SW, Nyström L, et al. The Guthenburg Breast Cancer Screening Trial. Cancer. 2003;10:2387–96. 5. International Agency for Research on Cancer. Chapter 3. Use of breast cancer screening. In Harri V, Franca B, eds. IARC Handbooks on Cancer Prevention. Vol. 7. Breast cancer screening. Lyon: IARC press, 2002. p.47–86. 6. Köse MR, Başara B, Güler C, Çağlar İ, Özdemir TA, Aygün A, et al. Sağlık İstatistikleri Yıllığı 2016, Sağlık Araştırmaları Genel Müdürlüğü, Sağlık Bakanlığı, Yayın No: 1083, Ankara, Türkiye, 2017. ss.38-39 7. Özmen V. Breast Cancer in the world and Turkey. J Breast Healt. 2008;4: 7-12. 8. T.C.Sağlık Bakanlığı. Refik Saydam Hıfzıssıhha Merkezi Başkanlığı Hıfzıssıhha Mektebi Müdürlüğü, Başkent Üniversitesi, ulusal hastalık yükü ve maliyet etkililik projesi, hastalık yükü final rapor. Ankara: 2004. 9. American Cancer Society. Cancer Facts & Figures 2012. Atlanta: American Cancer Society; 2012.